Maryam Hashemi

Dr. Maryam Hashemi


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Life Sciences
Verified
Journal Article
Closed access
SBSamaneh Bayat
Samaneh Bayat
NANafise Amiri
Nafise Amiri
EPElham Pishavar
Elham Pishavar
FKFatemeh Kalalinia
Fatemeh Kalalinia
JMJebraeel Movaffagh
Jebraeel Movaffagh
MHMaryam Hashemi
Maryam Hashemi

1 May 2020 in Journal of Controlled Release
Verified
Journal Article
Closed access
FOFatemeh Oroojalian
Fatemeh Oroojalian
FCFahimeh Charbgoo
Fahimeh Charbgoo
MHMaryam Hashemi
Maryam Hashemi
AAAmir Amani
Amir Amani
RYRezvan Yazdian-Robati
Rezvan Yazdian-Robati
Michael R. HamblinMichael R. Hamblin
Michael R. Hamblin

28 September 2017 in Artificial Cells, Nanomedicine, and Biotechnology
Verified
Journal Article
Closed access
MAMaryam Afsharzadeh
Maryam Afsharzadeh
MHMaryam Hashemi
Maryam Hashemi
AMAhad Mokhtarzadeh
Ahad Mokhtarzadeh
KAKhalil Abnous
Khalil Abnous
MRMohammad Ramezani
Mohammad Ramezani
Cancer is a broad term for a class of prevalent diseases as one in three people develop cancer during their lifetime. Although, there are few success stories of cancer therapy, most of the existing medications do not lead to complete recovery. Because of the complexity of cancer, usually a single therapeutic approach is insufficient for the suppression of cancer growth and metastasis. Simultaneous loading and co-delivery of different agents with different physiochemical characteristics to the same tumors have been suggested for minimizing the dose of anticancer drugs and achieving the synergistic therapeutic impacts in cancers treatment. Intense work to develop nanotechnology-based systems as a suitable option for cancer treatment is currently underway. The purpose of this review is to provide an overview of the co-delivery systems based on polymeric nanoparticles including polymeric micelles, dendrimers, poly-d,l-lactide-co-glycolide, polyethylenimine, poly(l-lysine) and chitosan for efficacious cancer therapy.

1 January 2017 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
PPParia Pashazadeh
Paria Pashazadeh
AMAhad Mokhtarzadeh
Ahad Mokhtarzadeh
MHMohammad Hasanzadeh
Mohammad Hasanzadeh
MHMaryam Hejazi
Maryam Hejazi
MHMaryam Hashemi
Maryam Hashemi
MMiguel de la Guardia
Miguel de la Guardia

28 March 2016 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
AMAhad Mokhtarzadeh
Ahad Mokhtarzadeh
AAAbbas Alibakhshi
Abbas Alibakhshi
HYHajar Yaghoobi
Hajar Yaghoobi
MHMaryam Hashemi
Maryam Hashemi
MHMaryam Hejazi
Maryam Hejazi
MRMohammad Ramezani
Mohammad Ramezani
Introduction: Gene therapy mainly depends on the use of appropriate delivery vehicles with no induction of immune responses and toxicity. The limitations of viral gene carriers such as induction of immunogenicity, random integration in the genome of the host, limitations in the size, has led to a movement toward non-viral systems with much safer properties. Biodegradable and biocompatible polymeric nanocarriers due to several unique properties such as excellent biocompatibility, prolonged gene circulation time, prevented gene degradation, passive targeting by using the enhanced permeability and retention (EPR) effect, and possibility of modulating polymers structure to obtain desirable therapeutic efficacy, are among the most promising systems for gene delivery. However, biodegradable gene delivery systems have some limitations such as inadequate stability and slow release of therapeutics which have to be overcome. Thus, a variety of advanced functional biodegradable delivery systems with more eff...

1 May 2015 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
MMMarzieh Mohammadi
Marzieh Mohammadi
ZSZahra Salmasi
Zahra Salmasi
MHMaryam Hashemi
Maryam Hashemi
FMFatemeh Mosaffa
Fatemeh Mosaffa
KAKhalil Abnous
Khalil Abnous
MRMohammad Ramezani
Mohammad Ramezani